Loading…
Company reports potential slowing of disease progression.
AC Immune SA (XNAS: ACIU) announced on December 11, 2025, positive interim Phase 2 data for its anti-alpha-synuclein active immunotherapy, ACI-7104.056, designed for early Parkinson’s disease. The interim analysis showed a 100% responder rate and antibody titers over 500-fold higher than baseline in 34 patients. Of the 20 participants evaluated at week 76, results indicated a potential slowing of disease progression compared to placebo.
The study duration was 74 weeks, with key evaluations at week 50 and week 74. The company noted significant antibody responses and a favorable safety profile. AC Immune has 40,064,900 shares in free float.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.